VIVUS Slumps On Higher Loss (VVUS, PSTI, ACAD, MIPS, LF, CTRP)

VIVUS, Inc.(NASDAQ:VVUS) tumbled 22% in early trade after the company reported net loss of $40.40 million or 10 cents a share in the third quarter, widened from a year ago loss of $8.63 million or 10 cents a share.  The company’s increased loss was largely due to increased spending related to selling, general and administrative expenses related to pre-commercialization and commercialization activities for Qsymia. Net product revenues came in at $41K from prescriptions shipped from certified pharmacies to patients.

Is It the Right Time to Buy VVUS after Today’s Slump? We Have Special Report Here

Analysts were estimating the company to report a loss of 34 cents a share.

Pluristem Therapeutics Inc.(NASDAQ:PSTI) shares gained 5.28% to $3.59. The company announced a milestone in the build-out of its new clinical Good Manufacturing Process (cGMP) manufacturing facility for its Placental eXpanded (PLX) cells in MATAM Park, Haifa, Israel. PSTI has initiated the Installation Qualification (IQ) validation process through Biopharmax Group Ltd., the company which is handling the build-out of Pluristem's facility.

MIPS Technologies, Inc.(NASDAQ:MIPS) stock increased 1.88% to $7.15. The company announced it has entered into separate definitive agreements with Bridge Crossing LLC ("Bridge Crossing"), an acquisition vehicle of Allied Security Trust ("AST"), and Imagination Technologies Group plc (LSE:IMG) ("Imagination") with net proceeds of approximately $7.31 per share in cash to each holder of MIPS common stock. The total value of the transaction represents a 40% premium to the closing price on April 11, 2012, the day prior to the first public rumor of a potential sale of MIPS.

LeapFrog Enterprises, Inc.(NYSE:LF) shares fell 3.13% to $9.29 after the company reported third quarter net income of $41.7 million or $0.60 per share, as compared to $23.0 million or $0.35 per share for the year-ago quarter. Adjusted net income per diluted share increased $0.20 per share compared to the prior year. Net sales for the third quarter rose 28% to $193.07 million from $150.83 million a year ago. Analysts expected the company to earn $0.42 per share on revenue of $174.19 million for the third quarter.

ACADIA Pharmaceuticals Inc.(NASDAQ:ACAD) shares gained 11.01% to $2.52. The company issued its quarterly earnings data yesterday. The company reported ($0.04) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.09) by $0.05. The company had revenue of $3.50 million for the quarter, compared to the consensus estimate of $1.90 million.

How Should Investors Trade ACAD After Today’s Gain? Get Free Trend Analysis Here International, Ltd. (ADR)(NASDAQ:CTRP) stock increased 2.74% to $20.60 after the company posted third quarter net income of RMB194 million or US$31 million, a decrease of 40% from the same period in 2011. Earnings per ADS were RMB1.41 or US$0.22 for the third quarter of 2012, down from RMB 2.13 last year. Adjusted net income was RMB302 million or US$48 million, a decrease of 27% from the same period in 2011. Adjusted earnings per ADS were RMB2.20 or US$0.35 for the third quarter of 2012. Total revenues were RMB1.25 billion or US$198 million, a 20% increase from the same period in 2011. Analysts expected the company to report earnings of $0.17 per share on revenues of US$182.13 million for the quarter.

You have read this article ACAD / CTRP / LF / MIPS / PSTI / VVUS with the title VIVUS Slumps On Higher Loss (VVUS, PSTI, ACAD, MIPS, LF, CTRP). You can bookmark this page URL Thanks!

No comment for "VIVUS Slumps On Higher Loss (VVUS, PSTI, ACAD, MIPS, LF, CTRP)"

Post a Comment